Specialty Infusion Market Intelligence
A specialty-infusion market thesis translated into ranked accounts, geographic priorities, a CRM-ready field plan and a working decision interface.
Return to verified workA market-entry thesis converted into a field-ready growth intelligence product
Evidence register
What this case can support.
- Evidence class
- Operating architecture
- Claim boundary
- This is a market-intelligence and application build. Account counts and QA results describe the built system, not client adoption, booked pipeline, or realized infusion revenue.
- Source basis
- Public and provider-directory data
- ICP, ZIP, account, and activation workbooks
- Local application QA and demo artifacts
Case architecture
Ecosystem thesis
Infusion growth depends on more than identifying specialists. Drug mix, payer access, site-of-care economics, referral behavior, geography, provider density, patient travel, operational capacity, and account readiness have to be translated into one field system.
System path
- 01Public signal
- 02ICP universe
- 03ZIP heat
- 04Activation queue
- 05CRM motion
Executive decision brief
CEO question
Which corridor merits field investment after referral access, payer fit and delivery capacity are tested?
Operating answer
Market intelligence should direct the next field decision: which accounts to pursue, where to launch, what to validate and how leadership will assess progress.
Proof to inspect
The proof is the built intelligence system and its verified scope: thousands of normalized accounts and locations, prioritized activation lanes, a working interface, and clean QA. It is not a claim of client adoption or booked revenue.
Ecosystem context
The conditions that shaped the work.
A raw provider list hides the decisions a market team actually needs to make: which accounts matter, which ZIPs can support access, which specialties and therapies create a viable wedge, and what sequence turns market interest into a functioning referral corridor.
I connected account discovery, source lineage, geographic opportunity and CRM states so the market thesis could produce a finite field allocation. A high-ranked account remains a hypothesis until local evidence establishes referral authority, payer access, therapy fit and the capacity to accept patients. The interface is designed to carry that uncertainty into the next action.
Because the source data is public or proxy-based, the system makes its boundary explicit: it guides market development and prioritization while reserving claims-based utilization conclusions for future validation.
Outcome record
The proof signals attached to the case.
ICP universe
A source-aware specialty-access target universe.
Activation queue
Priority accounts separated from broad market coverage.
Opportunity map
Geographic density translated into launch sequence.
Application QA
No console errors or failed requests in the recorded validation.
Interoperability map
How the layers connect.
Follow how the market signal informs the economics, how the workflow responds, and what evidence supports the next decision.
ICP Universe
Which accounts belong in the market?Public provider and location data were normalized into a 4,956-account decision universe.
Opportunity Geography
Where can access and density support launch?ZIP-level opportunity and provider-location layers made geographic concentration visible.
Activation Motion
Who moves first, and what happens next?A/B tiers, a 12-week queue, next actions, and CRM states translated research into field cadence.
Decision Product
Can leadership inspect and govern the motion?A working application connected account building, market maps, pipeline, QA, and executive visibility.
Operating record
The work, the sequence, and the strategic read.
Read the starting conditions, the work performed and the strategic interpretation separately. Together, they explain both the decision and the limits of the evidence.
Challenge
Replace a broad specialty-infusion market thesis with a precise, source-aware system that a growth team could use to prioritize geography, accounts, therapies, and next actions.
Approach
Built a market-intelligence application and operating dataset spanning ICP definition, ZIP opportunity, provider locations, target tiers, activation sequencing, CRM pipeline, and QA.
Founder takeaway
Market intelligence should direct the next field decision: which accounts to pursue, where to launch, what to validate and how leadership will assess progress.
Strategic read
The case combines market strategy with data and product delivery. The working application gives the field team account priorities and next actions while keeping source limitations visible.
Proof interpretation
The proof is the built intelligence system and its verified scope: thousands of normalized accounts and locations, prioritized activation lanes, a working interface, and clean QA. It is not a claim of client adoption or booked revenue.
Operator moves
- Structured a 4,956-account ICP universe and a 244-account A/B activation queue.
- Mapped 195 ZIP opportunity zones and more than 9,000 public provider-location rows.
- Created a 160-account activation plan and a 500-account CRM-ready pipeline.
- Built account discovery, map, pipeline, and execution views into one working interface.
- Validated the experience with no console errors or failed requests in the recorded QA pass.
Expansion path
- 01
Validate the top accounts and geography with local commercial evidence.
- 02
Add claims and payer data only under an explicit data-governance model.
- 03
Connect capacity, therapy, access, and site-of-care assumptions to account scoring.
- 04
Run the first 12-week activation cadence and measure progression quality.
- 05
Promote only repeatable market patterns into the expansion playbook.
What I would do again
- Make source lineage visible beside every score.
- Separate market potential from claims-validated utilization.
- Design the CRM handoff while building the market map.
The decision principle
I would commit field capacity where the next conversation can resolve a commercially consequential uncertainty. Public-data density can guide discovery; investment in a corridor still requires local confirmation of referral access, payer fit and delivery economics.
Discuss a related mandate
Bring the decision into focus.
For healthcare leaders connecting market choices, payer economics, partnerships and delivery capacity to an accountable plan.